Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides by Ahmed, Kariem et al.
Subscriber access provided by Universitätsbibliothek Bern
Nano Letters is published by the American Chemical Society. 1155 Sixteenth Street
N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Communication
Self-assembly into nanoparticles is essential for receptor
mediated uptake of therapeutic antisense oligonucleotides
Kariem Ahmed, YOSHITSUGU AOKI, Taeyoung Koo, Graham McClorey, Leif Benner, Anna
Coenen-Stass, Liz O'Donovan, Taavi Lehto, Antonio Garciaguerra, Joel Zacharias Nordin,
Amer F. Saleh, Mark A. Behlke, John Morris, Aurelie Goyenvalle, Branislav Dugovic, Christian
Joerg Leumann, Siamon Gordon, Michael J. Gait, Samir El-Andaloussi, and Matthew J.A. Wood
Nano Lett., Just Accepted Manuscript • DOI: 10.1021/acs.nanolett.5b00490 • Publication Date (Web): 04 Jun 2015
Downloaded from http://pubs.acs.org on June 10, 2015
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a free service to the research community to expedite the
dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts
appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been
fully peer reviewed, but should not be considered the official version of record. They are accessible to all
readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered
to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published
in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just
Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor
changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers
and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors
or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
s
o
u
r
c
e
:
 
ht
tp
:/
/b
or
is
.u
ni
be
.c
h/
69
42
7/
 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
1 
 
Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic 
antisense oligonucleotides  
 
Kariem Ezzat 1*, Yoshitsugu Aoki 1,11*, Taeyoung Koo 1,2,3, Graham McClorey1, Leif Benner 1, 
Anna Coenen-Stass 1, Liz O'Donovan 4, Taavi Lehto 5, Antonio Garcia-Guerra6, Joel Nordin5, 
Amer F. Saleh 4, Mark Behlke7, John Morris 1, Aurelie Goyenvalle8, Branislav Dugovic9, 
Christian Leumann9, Siamon Gordon10, Michael J. Gait4 , Samir El–Andaloussi1,5 and Matthew 
JA Wood 1. 
 
1Department of Physiology, Anatomy and Genetics, University of Oxford, OX13QX, Oxford, 
UK 
2Center for Genome Engineering, Institute for Basic Science, Seoul, South Korea    
3Functional Genomics, University of Science and Technology, Daejeon, South Korea  
4Medical Research Council Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK 
5Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden 
6Clarendon Laboratory, Department of Physics, University of Oxford, OX13PU, Oxford, UK 
7Integrated DNA Technologies (IDT), Coralville, Iowa, USA 
8Université de Versailles Saint Quentin, Montigny le Bretonneux, France 
9Department of Chemistry & Biochemistry, University of Bern, Bern, Switzerland 
Page 1 of 37
ACS Paragon Plus Environment
Nano Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2 
 
10Sir William Dunn School of Pathology, University of Oxford, OX1 3RE, Oxford, UK 
11Department of Molecular Therapy, National Institute of Neuroscience, National Center of 
Neurology and Psychiatry (NCNP), Tokyo, Japan 
 
*These authors contributed equally to this work. 
Correspondence should be addressed to: matthew.wood@dpag.ox.ac.uk 
 
 
Abstract 
Antisense oligonucleotides (ASOs) have the potential to revolutionize medicine due to their 
ability to manipulate gene function for therapeutic purposes. ASOs are chemically modified 
and/or incorporated within nanoparticles to enhance their stability and cellular uptake, however, 
a major challenge is the poor understanding of their uptake mechanisms, which would facilitate 
improved ASO designs with enhanced activity and reduced toxicity. Here, we study the uptake 
mechanism of three therapeutically relevant ASOs (peptide-conjugated phosphorodiamidate 
morpholino (PPMO), 2’Omethyl phosphorothioate  (2’OMe) and phosphorothioated tricyclo 
DNA (tcDNA) that have been optimized to induce exon skipping in models of Duchenne 
muscular dystrophy (DMD). We show that PPMO and tcDNA have high propensity to 
spontaneously self-assemble into nanoparticles. PPMO forms micelles of defined size and their 
net charge (zeta potential) is dependent on the medium and concentration. In biomimetic 
conditions and at low concentrations, PPMO obtains net negative charge and its uptake is 
mediated by class A scavenger receptor subtypes (SCARAs) as shown by competitive inhibition 
Page 2 of 37
ACS Paragon Plus Environment
Nano Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3 
 
and RNAi silencing experiments in vitro. In vivo, the activity of PPMO was significantly 
decreased in SCARA1 knock-out mice compared to wild-type animals. Additionally, we show 
that SCARA1 is involved in the uptake of tcDNA and 2’OMe as shown by competitive 
inhibition and co-localization experiments.  Surface plasmon resonance binding analysis to 
SCARA1 demonstrated that PPMO and tcDNA have higher binding profiles to the receptor 
compared to 2’OMe. These results demonstrate receptor-mediated uptake for a range of 
therapeutic ASO chemistries, a mechanism that is dependent on their self-assembly into 
nanoparticles.  
  
Key words: Antisense oligonucleotides, self-assembly, nanoparticles, scavenger receptors, 
uptake mechanism, delivery 
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Antisense oligonucleotides (ASOs) can be designed to target DNA and RNA in a sequence-
specific manner to stop, alter or induce particular gene functions. Thus, they have emerged as a 
very promising new class of therapeutics that can target disease pathophysiology at the 
molecular genetic level with high specificity. One of the most advanced applications of ASOs is 
their use for manipulation of gene function through splice switching. ASOs can switch splicing 
patterns through sequence-specific targeting of pre-mRNA elements involved in exon 
recognition and/or consensus splice sites in a sequence-specific manner 1.  This approach has 
been investigated as potential treatments for different types of muscular dystrophies, especially 
Duchenne muscular dystrophy (DMD), where ASOs have been extensively tested in disease 
models and are currently being evaluated in several clinical trials 2,3. DMD is caused by loss of 
function of the DMD gene due to deletions and/or mutations that cause the generation of 
premature termination codons and/or out-of-frame transcripts 4. Targeting of splice sites or 
putative exon splicing enhancers with ASOs can induce the removal of exons from the mature 
DMD transcript such that a nonsense mutation is bypassed, or alternately removal of exons 
around a genomic deletion can restore the mRNA reading frame.   
Chemical modifications are introduced into ASOs to enhance their stability against nucleases and 
to prevent immune stimulation 5.  Despite the promising results of the ongoing trials using ASOs, 
major scientific challenges remain. The principle limitation of ASOs is their poor cellular uptake 
due to their large molecular weight and mostly highly charged nature. Paradoxically, in practice, 
ASO uptake is dramatically enhanced when they are incorporated with nanoparticles that are 
even larger in size and much richer in charge. Most transfection reagents and ASO delivery 
systems rely on complexation or loading ASOs into nanoparticulate vectors 6. Moreover, under 
certain conditions, naked ASOs of different chemistries are taken up by cells without the need 
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for transfection reagents in a process termed “gymnosis” via an unknown mechanism 7. Thus, 
understanding the uptake mechanism and resolving these seemingly paradoxical observations is 
very important for the clinical development of ASOs. Here we study the uptake mechanism of 
three ASO compounds of different chemistries that have been optimized for skipping of exon 23 
in preclinical or clinical studies of DMD.  
The first compound is from the peptide- morpholino family (PPMOs), which comprises a cell-
penetrating peptide (CPP) attached to phosphorodiamidate morpholino oligomer; PMO 8. PMOs 
possess a morpholino moiety instead of the ribose moiety and the backbone phosphodiester 
linkages are replaced with uncharged phosphorodiamidate linkages. CPPs are short cationic 
peptides that enhance the uptake of the PMO into cells 8. Here, we mainly use the B-peptide 
conjugated PMO (B-PMO), a classical PPMO example, as our model 9.  The second ASO is 
from the second generation of chemically modified RNAs; phosphorothioate 2’OMe. The 2’OH 
is replaced by a 2’OMe group and the phosphodiester linkages in the backbone are replaced by 
the more stable phosphorothioate linkages 5.  The third ASO is from the recently developed 
family of tricyclo DNA (tcDNA). TcDNA has three additional C-atoms between C5’ and C3’ 
which increase both the affinity and hydrophobicity of the molecule together with a 
phosphorothioate backbone 10. Both 2’OMe and tcDNA chemistries have been shown to be taken 
up by cells via gymnosis7,11. All three molecules have been extensively tested in the well-
established mdx mouse model for DMD, which carries a nonsense mutation in exon 23 of the 
Dmd gene. Of the three ASO classes, PPMOs are the most potent, achieving high levels of exon 
skipping in different skeletal muscles at doses as low as 6 mg/kg 9,12. TcDNA is the second most 
potent chemistry tested here, with a superior activity over 2’OMe when administered at a dose of 
200 mg/kg demonstrating effective exon skipping even in the brain 13.   
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Recently, we have demonstrated that a class of pattern recognition receptors (PRRs), namely 
scavenger receptors (SRs), is involved in the uptake of certain CPPs when complexed with ASOs 
14. SRs are a large family of PRRs that are involved in the uptake of pathogen associated 
molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) and play 
important functions in innate immunity and homeostasis 15.  They are subdivided into several 
classes, from A to I, which are structurally diverse but functionally similar in their ability to bind 
polyanionic (negatively charged) particulate substrates15,16. The vast array of their ligands 
include: oxidized low density lipoprotein (oxLDL), acetylated LDL (acLDL), apoptotic cells, 
Staphylococcus aureus bacteria, HCV virus, lipopolysaccharide (LPS), PrP106–126 prion protein, 
viral RNA and different types of synthetic nanoparticles 15,17,18.  Little is known about the 
structural features that are responsible for the promiscuous binding of SRs to negatively charged 
ligands; however, it is hypothesized that the surfaces that are engaged in ligand binding are 
similar in terms of shape and charge distribution, displaying clusters of cationic residues 
(cationic patches) 15. Additionally, due to their observed low specificity and functional overlap, 
they are thought to function in the form of heteromultimeric receptor complexes (signalosomes) 
that comprise SRs and other co-receptors 15.  SRs are highly expressed in professional immune 
cells such as macrophages, but have also been shown to be expressed other cell types including 
smooth muscle cells, endothelial cells, fibroblasts, splenic dendritic cells, and epithelial cells 19.  
Class A SRs (SCARAs) are among the most extensively studied SRs and are characterized 
structurally by their collagenous domains 20.  SCARAs have different subtypes, including 
SCARA1 (SR-AI), SCARA2 (MARCO), SCARA3, SCARA4 (Colec12), and SCARA5, among 
which SCARA3 and SCARA5 have been shown earlier to be involved in uptake of CPP-ASO 
nanocomplexes 14.  
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Here we study the effects of the physicochemical properties of the three different ASO 
compounds (PPMO, phosphorothioate 2’OMe, phosphorothioate tcDNA) used for the treatment 
of DMD and the role of SRs in their uptake, especially in muscle cells. We hypothesize that 
variation in ASO activity is due to their physicochemical properties modulated by their ability to 
self-assemble and to bind to SRs. 
 
RESULTS AND DISCUSSION 
PPMO and tcDNA have high propensity to spontaneously self-assemble into nanoparticles. 
Physicochemical properties including particle size and charge are important determinants for 
uptake of drug delivery systems. Recently, using transmission electron microscopy (TEM) and 
nanoparticle tracking analysis, we found that tcDNA has a higher propensity to self-assemble 
into nanoparticles compared to 2’OMe 13. To investigate this further in comparison to the PPMO 
chemistry we used dynamic light scattering (DLS). In accordance with our previous 
observations, the predominant peak in the tcDNA sample was a broad particulate peak (Fig. 
1A.). For PPMO, there were two peaks, one for singular molecules and one representing a 
particulate population. However, for 2’OMe, the predominant peak was of singular molecules at 
around 2 nm together with another particulate peak of much less intensity (Fig. 1A.). 
Comparatively, these results show that both tcDNA and PPMO have a higher propensity to form 
nanoparticles than 2’OMe. In order to make sure that this property of self-assembly is retained in 
physiological conditions; we repeated the DLS measurements after incubation with physiological 
concentrations of albumin solution in PBS for 1h at 37 ºC. Albumin is the most abundant serum 
protein representing up to 50% of total serum protein 21. While it is difficult to run DLS in the 
presence of full serum due to high background from diverse proteins, a simplified albumin based 
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model generates one distinct peak of albumin around 4 nm, which also acts as an internal 
standard. Importantly, in this model, only tcDNA and PPMO were able to display high intensity 
particulate peaks, while 2’OMe failed to do so (Fig. S1 A). To test full serum conditions on these 
ASOs, fluorescently labelled tcDNA and PPMO were incubated with full serum for 1h at 37 ºC, 
and subsequently fractionated using a continuous sucrose gradient. The fraction with the highest 
fluorescence signal was visualized via fluorescence microcopy. Densely bright particulate 
structures were observed for tcDNA and PPMO under these conditions, showing that the process 
of self-assembly into nanoparticles is maintained in physiological conditions and in the presence 
of serum proteins (Fig. S1 B).  
 
Amphipathic PPMO forms micelles. To further investigate the nanoparticles formed by the 
PPMO, we used TEM visualization, as used previously for tcDNA and 2’OMe.  PPMOs formed 
well-defined nanoparticles with a diameter ranging between 30 and 90 nm (Fig. 1B). We 
speculated that this spontaneous nanoparticle formation is due to the amphipathicitiy of the 
PPMO structure that leads to self-assembly into micelles. The PPMO molecule is composed of a 
relatively hydrophobic PMO portion and a very hydrophilic CPP that harbors multiple positive 
charges, a structure susceptible to micelle formation. In fact, PMOs are among the most 
hydrophobic ASO chemistries available. A PMO adenosine monomer has an octanol-water 
partition coefficient (log P) of -2.72, while the log P for an adenosine nucleotide of the 2’OMe 
chemistry is -4.15, -4.39 for locked nucleic acid (LNA), and -3.43 for peptide nucleic acid (PNA) 
22. To confirm the micellization of PPMO, we utilized the dye micellization method 23; which is a 
classical method used to determine the critical micelle concentration (CMC). CMC is the 
concentration at which an amphipathic surface active molecule (surfactant) starts to self-
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assemble into micelles in the bulk of the dispersion medium 23. Dyes such as eosin, rhodamine 
and Sudan red are known to show a shift in the wavelength maximum (λ max) due to the 
presence of micelles 23. Here, we used eosin Y which has wavelength maximum at 518 nm in 
water; however, the presence of micelles increases its absorbance at 542 nm.  CMC can be 
determined by plotting the change in absorbance of the micellized dye at a fixed wavelength 
(542 nm) against surfactant concentration. The linear portion near the inflection point is 
extrapolated to intersect with the absorbance of the dye in the absence of any surfactant 
(represented by the horizontal line in Fig. 1C.), and this concentration is the CMC 23. PPMO 
behaviour was typical surfactant behaviour with a CMC of about 1.4 µM. The PPMO probably 
behaves similarly to multi-head-group surfactants; however, the complexity of the structure due 
to the presence of an atypical hydrophobic tail (the PMO in this case) and up to 10 charges might 
require the development of specific models to understand this process. 
 
PPMO charge reversal in biomimetic conditions. The net charge of a nanoparticle is a 
function of pH and the concentration of counterions in the medium. Thus, it is important to study 
the properties of therapeutic compounds in biomimetic conditions in terms of pH or isotonicity 
where their properties at these conditions are more relevant to their biological activity. We have 
previously demonstrated that certain CPPs, such as PF14 which is used for ASO delivery via 
non-covalent complexation, change their zeta potential according to the dispersion medium 14.  
To determine if the same is true for the self-assembled nanoparticles of PPMO, we measured the 
zeta potential in different conditions. Interestingly, PPMOs displayed the same pattern, having a 
positive zeta potential (10 ± 2.70) in water while changing into negative values in PBS (-1.21 ± 
0.63) and serum-free medium (-3.48 ±2.31) due to the change in pH and high salt concentration. 
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Surprisingly, this charge reversal was also concentration dependent as demonstrated by gel 
mobility shift assay (Fig. 1D). At high concentrations (50 µM), PPMO migrates towards the 
cathode, indicating a net positive charge, but as the concentration gets lower, the migration 
pattern shifts towards the anode indicating a net negative charge in a clear visualization of the 
charge reversal phenomenon.  These observations highlight the importance of the presence and 
concentration of counterions in the solution. An important parameter to consider here is ξ, which 
is the molar concentration ratio of counterions to surfactant 24. When ξ increases, more 
counterions bind to the micellar surface changing its net charge and this explains the 
concentration dependent charge reversal. At higher PPMO concentrations ξ is low; hence, there 
are not enough counterions in the running buffer to shield and reverse the exposed cationic 
groups on the micellar surface; and thus, migration occurs towards the cathode. As the PPMO 
concentration is decreased, the ξ ratio changed in favor of the concentration of counterions in the 
running buffer enabling shielding and reversal of the net surface charge and migration to the 
opposite pole. The same effect can be replicated by keeping the PPMO concentration constant 
while changing the concentration of the counterions. When using TBE as a running buffer with 
equimolar concentrations of the cationic basic species (Tris base) and the anionic acidic species 
(boric acid), PPMO migration pattern can be seen to be divided between both the anode and the 
cathode (Fig. S1 C). Interestingly, when using unbalanced TBE with excess basic species, the 
migration pattern shifts towards the cathode indicating net positive charge, and the opposite takes 
place upon using TBE with excess boric acid. This further supports our hypothesis that the net 
charge of the PPMO depends on the delicate balance between the concentration of the PPMO 
and the concentration of the counterions available in the medium.   
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Class A scavenger receptors are involved in PPMO uptake. As aforementioned, we have 
shown previously that the uptake of certain CPP complexes with ASOs is mediated by class A 
scavenger receptor subtypes (SCARAs) 14. To determine whether the change in charge of the 
PPMO also mediates uptake through SCARAs, we tested the effects of SCARA ligands on the 
PPMO splice-switching activity in the C2C12 muscle cell line. Fucoidin sulfate and dextran 
sulfate are well-known SCARA ligands, and chondroitin sulfate is a chemically related molecule 
but not a specific ligand; and thus serves as a negative control. Cells were treated with the 
ligands or the control for 1h before treatment with the PPMO for 4 h, after which the medium 
was changed and cells were incubated for 20 h. Both fucoidin sulfate and dextran sulfate 
completely inhibited the splice-switching activity of the PPMO while chondroitin sulfate had no 
effect (Fig. 2A).  This competitive inhibition demonstrates the involvement of SCARAs in the 
uptake and activity of PPMO. 
Moreover, several SCARA subtypes were expressed in the C2C12 murine myoblast cell line, 
including SCARA1, 3, 4 (COLEC12) and 5 (Suppl. Fig. S2A). We next tested the effect of 
silencing the expressed SCARA subtypes on PPMO activity. Upon using an siRNA cocktail 
against all the expressed SCARA subtypes (1, 3, 4 and 5), the splice-switching activity of PPMO 
was significantly reduced (Fig. 2B). We have recently demonstrated that the uptake and activity 
of PPMOs was higher in differentiated myotubes compared to undifferentiated myoblasts both in 
C2C1225 and H2k mdx cell-lines 26, both of which represent common models to study muscle 
differentiation. Interestingly, the expression of SCARA subtypes increases significantly 
throughout the course of differentiation of both cell lines, which correlates closely with the 
observed difference in PPMO uptake and activity (Fig. S2). Additionally, we performed TEM 
and SCARA inhibition analysis to ensure that this PPMO (Pip6a-PMO) behaves similarly to the 
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model PPMO we are testing here (B-PMO). Pip6a peptide design is broadly similar to the B-
peptide but with the inclusion of a YQFLI core motif within the arginine rich sequence 27. This 
change enhanced its splice-switching activity in vivo especially in the heart; however, the cause 
of this enhanced activity was not known.  Here we show that Pip6a-PMO, similar to the B-PMO, 
spontaneously forms nanoparticles that can be visualized via TEM and that its uptake is 
significantly inhibited in the presence of SR ligands (Fig. S3). Interestingly, Pip6a-PMO 
nanoparticles are smaller than B-PMO nanoparticles; a property that may contribute to its 
enhanced biodistribution profile. Importantly, when injected in vivo in SCARA1 knock-out mice 
28, the activity of Pip6a-PMO was significantly reduced in the diaphragm and heart compared to 
wild-type (WT) mice (Fig. 2C). This demonstrates that the SR dependent interactions observed 
in vitro also contribute to the biological activity of PPMOs in vivo. This does not exclude 
however the involvement of other receptor subtypes (SCARA3,4 and 5)  and other SR classes in 
this process. The residual activity in the diaphragm and non-significant differences in tibialis 
anterior (TA) might very likely be due to compensation and differential expression of other SRs 
that are not altered in their expression in this model.   
It is important to note that these observations for PPMOs could have more general implications 
on understanding the mechanism of action of both CPPs and antimicrobial peptides (AMPs).  
Several secondary amphipathic CPPs are known to self-assemble into nanoparticles 29. 
Furthermore, Kohno et al. 30 have recently shown that the uptake of an antimicrobial peptide 
(K8L9) at subcytotoxic concentrations is mediated by neuropilin-1 and low-density lipoprotein-
related protein receptor 1 (LRP1), a receptor with scavenger like properties.  Moreover, using 
siRNA screens, Kondo et al. 31 demonstrated the involvement of M160 (CD163L1; scavenger 
receptor cysteine-rich type I) in the uptake of a tumor homing CPP (CPP44).  This shows that the 
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phenomena of self-assembly and SR interaction are more general and that several SR receptor 
classes might be involved in the CPP/AMP mechanism of action; however, the details of their 
complimentary, synergistic or compensatory mechanisms require further studies. Additionally, 
the observation that net charge is dependent on concentration might explain different 
mechanisms of activity for CPPs and/or AMPs. At low concentrations, when there are sufficient 
counterions to shield and reverse the positive charge, receptor-mediated uptake might be the 
predominant mechanism of action. However, at high concentrations, when the net charge is 
positive, direct membrane interactions might predominate; which could explain lytic and toxic 
effects at such concentrations.  
 
Varied involvement of SRs in the uptake of PPMO, tcDNA and 2’OMe chemistries. To 
determine the involvement of SRs in the gymnotic uptake of the other ASO chemistries we 
tested the effect of several SR ligands on the uptake of naked tcDNA and 2’OMe. The uptake of 
FITC-tcDNA and FITC-2’OMe was monitored in the presence of polyinosinic acid (poly I), 
polycytidylic acid (poly C), fucoidin sulfate, dextran sulfate and chondroitin sulfate. While 
fucoidin and dextran sulfates are more specific for SCARAs, poly I is more general as it also 
targets class C (SR-CI),  class E (ORL-1/Lox-1) and class F (SREC) SRs 32 in addition to other 
receptors with scavenger properties such as Mac133 and nucleolin which binds quadruplex DNA 
structures 34,35.  Poly C serves as the control for poly I. The uptake of tcDNA and 2’OMe was 
only partially inhibited in the presence of fucoidin and dextran sulfates, but almost completely 
inhibited in the presence of poly I (93.6% and 89.0% respectively) (Fig. 3) demonstrating the 
involvement of SCARAs together with other poly I sensitive SRs in the uptake, probably in 
heteromultimeric signalosome complexes. SRs have been previously suggested to be involved in 
Page 13 of 37
ACS Paragon Plus Environment
Nano Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14 
 
the uptake of negatively charged ASOs 36-39, and it has been shown that the formation of 
multimers or the capacity to form G-quadruplexes enhance the uptake and activity of naked 
ASOs 40-42. This aggregation was also shown to enhance binding to SRs 43,44. Thus, it is feasible 
to speculate that the superior activity of tcDNA is related to its propensity to self-assemble into 
nanoparticles mediating better SR interaction and subsequent gymnotic uptake. Indeed, we 
observed that the extent of uptake of fluorescently labelled tcDNA is significantly higher than 
that of 2’OMe despite having similar biological activity upon lipofection (Fig. S4). Equivalent 
biological activity using lipofection was also demonstrated using sequences targeting exon 51 
(Fig. S4D).   This shows that despite other factors that might contribute to the superior activity of 
tcDNA (mRNA binding for example), a higher uptake profile due to higher propensity to form 
nanoparticles significantly contributes to this increased activity. This is more evident in the case 
of PPMO, which displays several folds higher uptake than the other two chemistries (Fig. S4). 
Furthermore, we studied the effect of other factors on the uptake of the ASOs. Incubation at 4 ºC 
significantly reduced the uptake of all the chemistries indicating the involvement of an active, 
energy-dependent mechanism of uptake (Fig S4). Incubation in the presence of serum on the 
other hand had only a small negative effect on uptake (Fig. S4), which might be due to the high 
stability of these heavily chemically modified ASOs.  
The mechanism of spontaneous tcDNA self-assembly is not well understood. While tcDNA 
lacks the dichotomy of structure of the PPMO, the three additional C-atoms increase the 
hydrophobicity of the molecule. We speculate that this increased hydrophobicity might impart 
secondary amphipathic properties on the structure enabling self-assembly via mechanisms 
resembling the self-assembly of secondary amphipathic peptides 29. Alternatively, the extra rings 
in the tcDNA might facilitate stacking and generation of structures resembling poly-G aggregates 
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that were seen to enhance the uptake of ASOs and binding to SRs 41-44. Structural and molecular 
modeling studies are underway to unravel the mechanism of tcDNA self-assembly.  
 
Co-localization and SCARA1binding. To demonstrate direct association between ASOs and 
receptor we performed co-localization experiments and Surface Plasmon Resonance (SPR) 
binding analysis. Immunocytochemical analysis using an anti-SCARA1 antibody showed co-
localization of all three ASO compounds with the receptor (Fig. 4A). Furthermore, SPR was 
used to comparatively study the relative binding of the different chemistries to SCARA1.  His-
tagged SCARA-1 receptors were immobilized on the chip using an anti-His-tag antibody. 
Response units were calculated for specific binding after subtraction of non-specific binding to 
the chip or the antibody. PPMO demonstrated the highest binding followed by tcDNA, while 
2’OMe displayed minimal binding (Fig. 4B). It was evident that the chemistries that are able to 
form nanoparticles demonstrated more efficient binding to the receptor, which is in accordance 
with the mode of action of SRs.  
 
CONCLUSIONS 
Our data shows that two potent ASOs, PPMO and tcDNA, have a higher propensity to self-
assemble into nanoparticles and better binding to SCARA1 compared to the less potent 2’OMe.  
We hypothesize that nanoparticle assembly enhances ASO uptake based on the particle-
wrapping model for receptor-mediated uptake of nanoparticles 45,46. In this model, optimal 
uptake requires a certain threshold of particle size. Below this threshold uptake will be impeded 
by the high energy cost required for a high curvature of the membrane to wrap the particle, and 
above it the uptake will be limited by the number of the receptors available for efficient particle 
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wrapping 47.  An optimal radius for uptake has been predicted theoretically to be around 25-30 
nm and has also been validated experimentally 48. Interestingly, TEM pictures show that both 
PPMO and tcDNA13 nanoparticles are within this size range. Thus, the self-assembly process is 
important for mediating this type of interaction through SRs. The importance of the self-
assembly process for uptake can be depicted in a model were single ASO molecules fail the 
criteria required for passive uptake into cells due to charge and  size restrictions (Lipinski rule of 
5 49), however, they can gain access via receptor mediated endocytosis only if they reach a 
certain size threshold (particle-wrapping model) (Fig. 5).  
Unlike preformed synthetic nanoparticles, this process is spontaneous and dynamic, which 
means that the particles form and deform under different conditions. However, the apparent high 
propensity to self-assemble increases the probability of PPMO and tcDNA to form nanoparticles 
in proximity to the cell surface compared to other chemistries. In this regard, PPMOs and tcDNA 
resemble in vivo nanoparticle-based delivery systems and in vitro transfection reagents without 
the need for exogenous delivery or complexing agents. Furthermore, the spontaneous and 
reversible nature of the self-assembly process can explain the enhanced biodistribution of 
PPMOs and tcDNAs to tissues that are inaccessible to conventional nanoparticles, like skeletal 
muscle for example. While preformed nanoparticles are unable to extravasate into most tissues 
except liver and spleen due to the size restriction of capillary fenestrations, we speculate that 
self-assembling chemistries are able to extravasate through capillary fenestrations as single 
molecules and reform nanoparticles upon accumulation and reaching high local concentrations in 
situ. However, more in vivo pharmacokinetic and biodistribution studies are needed to elucidate 
these mechanisms in more detail as a limitation of in vitro cell systems is that they differentially 
express proteins on their surface when compared to in vivo conditions.  
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We believe that such models are crucial for understanding the pharmacokinetics and dynamics of 
current ASO therapeutics for better design and development of new ASO chemistries and 
delivery vehicles.   Based on the findings discussed above, novel drug delivery platforms can be 
designed to enhance the propensity of self-assembly or to target SCARAs. These findings also 
highlight the importance of understanding the uptake mechanism for the clinical development of 
ASOs and pave the way for successfully applying ASOs to the treatment of genetic diseases. 
  
METHODS  
Antisense oligonucleotides (ASOs).  
All ASOs target the donor splice site of exon 23 of the mouse dystrophin pre-mRNA. The most 
efficient sequence was chosen for all chemistries from previously reported studies. TcDNA-PS 
(5’-AACCTCGGCTTACCT-3’) was synthesized by SYNTHENA, Bern. 2’OMePS (5’-
GGCCAAACCUCGGCUUACCU-3’) was synthesized by Integrated DNA Technologies (IDT, 
USA) and PMO (5’-GGCCAAACCTCGGCTTACCTGAAAT-3’) was ordered from Gene Tools 
LLC. Conjugations of peptide (B-peptide: RXRRBRRXRRBRXB, Pip6a: RXRRBRRXR 
YQFLI RXRBRXRB, X, 6-aminohexanoic acid; B, b-alanine) with PMO were synthesized 
through use of a stable amide linker as described elsewhere 50. 
 
DLS, TEM, CMC and zeta potential 
DLS measurements were performed on Viscotek 802 instrument (Malvern, USA) using 30 µl of 
1 mM ASO in PBS. DLS measurements in simulated physiologic conditions were performed by 
mixing equal volumes of the ASOs with filtered albumin (BSA, Sigma-Aldrich, Germany) 
solution in PBS (4.25 g/dL) at 37 ºC for 1h then measuring on the DLS machine after appropriate 
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dilution (10x). For TEM visualization, PPMO was mounted on formvar/carbon coated 200 mesh 
nickel grids (Agar Scientific, UK), then negatively stained using an aqueous solution of uranyl 
acetate and visualized using a JEOL 1010 transmission electron microscope (JEOL, Peabody, 
MA, USA) at 50,000 x magnification. For CMC measurements, eosin Y at a final concentration 
of 0.019 mM was mixed with different concentrations of PPMO (50, 25, 15, 12, 10, 9, 8, 7, 6, 5, 
4, 3, 2, 1, 0.5, 0.25, 0.125 µM). UV absorption was measured at 542 nm using Biotek Synergy 
HT spectrophotometer (Biotek, USA). Zeta potential measurements were carried out on a 
Zetasizer instrument (Malvern, USA). Charge reversal gel experiments were run on 1.25% 
agarose gel with ethidium bromide using different buffers including: TAE, TBE, TBE with 4x 
Tris and TBE with 4x boric acid and visualized using UV.  For visualization nanoparticles in 
serum, FITC-labelled ASOs were incubated in 100 µl of whole serum at a final concentration of 
10µM (Fetal Bovine Serum, Heat inactivated (FBS)) for 1 h at 37°C. After incubation, ASOs 
were layered on top of a sucrose gradient. The gradient was composed of seven 1.25 ml fractions 
of sucrose dissolved in PBS. The concentrations of the fractions from the top to the bottom were 
15%-45% in 5% increments. Once layered, the gradients’ interfaces were smoothened through 
diffusion by vertical incubation at 4°C overnight. The loaded gradients were spun in an 
ultracentrifuge (Beckman Coulter OptimaLE 80K) using a swinging bucket rotor (Beckman 
Coulter, SW 41Ti) at 200000 xg for 4h at 4°C. The gradients were then retrieved and 1ml 
fractions from top to bottom were collected (10 fractions in total per ASO). 100 µl per fraction 
were transferred to a clear bottom black plate and screened for fluorescence signal. The fractions 
with highest signal were loaded on a sandwiched coverslip-slide (two spacers made of double 
sided tape were used to fix the coverslip on the slide) treated with 50 µl of a 5mg/mL BSA in 
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PBS solution for 10 minutes and subsequently imaged using an oil immersion 100x objective in 
a Nikon Eclipse TE2000-U equipped with a Watec WAT-902H camera.  
 
Cell culture and PCR  
Murine C2C12 cells were grown in DMEM (Dulbecco's Modified Eagle Medium), high glucose, 
GlutaMAX media (Life Technologies, USA) with 10% fetal bovine serum (FBS, Life 
Technologies) and 1% penicillin/streptomycin (Life Technologies). Murine H2k mdx myoblasts 
were cultured in gelatin (0.01%)-coated flasks at 33 ºC, under 10% CO2, in Dulbecco’s modified 
Eagles medium (DMEM PAA laboratories) supplemented with 20% heat-inactivated fetal bovine 
serum (FBS Gold, PAA laboratories), 2% chicken embryo extract (Seralab), 1% 
penicillin/streptomycin- neomycin antibiotic mixture (Life Technologies) and 3 pg/ml g-
interferon (PeproTech).  For differentiation cells (1x105) were seeded into wells of a 24-well 
plate and the medium was changed after 24 h into differentiation medium consisting of DMEM 
containing 2% horse serum (Life Technologies) and differentiated for 3-4 days before 
experimentation. For PPMO treatment, cells were treated with a concentration of 500 nM in 
serum-free Opti-MEM® medium for 4 h, the medium was then changed for differentiation 
medium and incubation continued for a further 20 h. For RT-PCR detection of exon skipping, 
cells were lysed and RNA harvested using RNeasy kit (Qiagen, Germany) and quantified, then 
used for nested PCR procedure. Briefly, RNA was amplified on 2 steps with gene-specific 
primers (Ex 20-26, Fwd: CAG AAT TCT GCC AAT TGC TGA G-, Rev: TTC TTC AGC TTG 
TGT CAT CC) using Gene Amp PCR core kit (Life Technologies). Then cDNA was further 
amplified using Amplitaq Gold polymerase (Life Technologies, USA) with primers: Ex 20-26: 
Fwd: CCC AGT CTA CCA CCC TAT CAG AGC, Rev: CCT GCC TTT AAG GCT TCC TT). 
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PCR products were examined by electrophoresis on a 2% agarose gel. qPCR analysis was 
performed on cDNA from C2C12 and H2k mdx cells using 25 ng cDNA template and amplified 
with Taqman Gene Expression Master Mix (Applied Biosystems, Warrington, UK) on 
a  StepOne Plus Thermocycler (Applied Biosystems, Warrington, UK).  Taqman probes 
targeting SCARA1/3/4/5 (Life Technologies) were used and murine Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) probes were used as an internal control for cDNA levels.  
 
Scavenger receptor (SR) inhibition  
Differentiated C2C12 or H2k mdx (1x105) were treated with SR ligands and controls: fucoidin 
sulfate, dextran sulfate, chondroitin sulfate, polyinosinic acid, polycytidylic acid (Sigma-Aldrich, 
Germany) for 1 h before adding the ASOs. Cells were then treated with the ASOs and analyzed 
as stated above.  For siRNA treatment, C2C12 myoblasts differentiated for 24 h were treated 
with either a cocktail of  siRNAs, SACRA1,2,4 and 5, 25 nM each (siGenome SMART pool, 
Dharmacon, USA) or scrambled control siRNA (100 nM) using Lipofectamine RNAiMax® 
(Life Technologies) according to the manufacturer’s protocol. After 24 h, medium was changed 
and cells were treated with PPMO as explained earlier.  
 
Animal experiments 
Experiments were carried out in the Biomedical Sciences Unit, University of Oxford according 
to procedures authorized by the UK Home Office. SCARA1 -/- and C57BL/6 mice (14 month 
old, n = 4) were used. SCARA1-/- mice were generated by Professor Tatsuhiko Kodama 28, and a 
colony has been maintained in our lab since then. Pip6-PMO conjugates were prepared in 0.9% 
saline solution at a final dose of 10 mg/kg and administered via the tail vein. One week later 
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mice were sacrificed by CO2 inhalation, and tissues harvested and snap-frozen in cooled 
isopentane before storage at –80 °C. Total RNA was extracted from tissues using TRIzol reagent 
(Life Technologies) following manufacturer’s instructions. For quantitative analysis of exon 
skipping levels, 1 µg of RNA was reverse transcribed using the High Capacity cDNA RT Kit 
(Applied Biosystems, Warrington, UK) according to manufacturer’s instructions. qPCR analysis 
was performed using 25 ng cDNA template and amplified with Taqman Gene Expression Master 
Mix (Applied Biosystems, Warrington, UK) on a StepOne Plus Thermocycler (Applied 
Biosystems, Warrington, UK). Levels of Dmd exon 23 skipping was determined by multiplex 
qPCR of FAM-labelled primers spanning Exon 20-21 (Assay Mm.PT.47.9564450, Integrated 
DNA Technologies, Leuven, Belgium) and HEX-labelled primers spanning Exon 23-24 
(Mm.PT.47.7668824, Integrated DNA Technologies). The percentage of Dmd transcripts 
skipping exon 23 was determined by normalizing Dmd exon 23-24 amplification levels to Dmd 
exon 20-21 levels. 
 
Fluorescence microscopy and spectrophotometry 
For immunofluorescence, cells were treated with either Cy5 conjugated PPMO 51, or FITC 
conjugated 2′OMePS or tcDNA oligonucleotides for 4 hours then washed 3 times with PBS plus 
(PBS containing Ca2+ and Mg2+) solution, and fixed with methanol at -20° C for 10 minutes.  
Cells were then washed and stored in PBS at 4° C for future immunofluorescence. For co-
localization, cells were treated with 0.1% Triton-X100 (Sigma-Aldrich) in PBS for 10 minutes, 
and washed three times with PBS plus, then blocked with 1% bovine serum albumin (BSA, 
Sigma Aldrich) containing PBS for 1 h.  Cells were then incubated with rat anti-mouse SCARA1 
(1:200 dilution, Bio-Rad, Hercules, CA), then washed three times with PBS plus and treated with 
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1:500 Alexa Fluor 488 goat anti-rat (Life Technologies) for 1 h.  DAPI (1:5000 dilution, Sigma 
Aldrich) staining was then completed for 2 minutes, after which cells were washed and mounted 
with fluorescent mounting medium S3023 (Dako, Tokyo, Japan) onto glass slides.  Visualization 
was carried out on a Leica fluorescent microscope with pictures taken by Axiovision fluorescent 
camera and Axiovision software (Zeiss, Oberkochen, Germany). Spectrophotometric 
measurements for the uptake of FITC-labeleld ASOs were performed in tissue-culture coated 
black plates with clear optical bottom (Corning, USA) using Victor3 spectrophotometer (Perkin 
Elmer, USA) 24 h after ASO addition.   
 
SPR 
Binding experiments were performed with a Biacore 3000 system (GE Healthcare) using CM5 
chip. Anti-his-tag antibody was immobilized using amine coupling. Subsequently, His-tagged 
recombinant mouse SR-AI (SCARA1) (R&D Systems, USA) receptor was immobilized on a 
CM5 chip to give < 420 RU. For the binding assay, ASOs in PBS were injected at 10 µL/min at 
25 ºC. Data traces were zeroed in the x and y axis after subtraction of non-specific binding. 
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Figure Legends 
Figure 1. Characterization self-assembling nanoparticles. (A) DLS analysis of tcDNA, 
2’OMe and PPMO. Each was measured 3 times (different colors) at 1 mM concentration in PBS 
showing the profile of the different populations present. (B) Negatively stained TEM pictures of 
nanoparticles formed by PPMO; Bar = 100 nm. (C) Critical micelle concentration (CMC) 
determination of PPMO using the dye micellization method (absorbance at 542 nm). Eosin Y 
concentration: 0.019 mM. The X-axis represents log the concentration in nM. CMC is the 
inverse log of the point at the intersection between the linear portion of the curve near the 
inflection point (R2=0.924) and the absorbance of the dye in the absence of any surfactant 
represented by the horizontal line. CMC = 1380.38 nM.  (D) PPMO at different concentrations 
was loaded on a 1.25% agarose gel using TAE as running buffer. 
 
Figure 2. Involvement of SCARA in PPMO uptake. (A) Differentiated C2C12 cells (1x105) 
were pretreated SR ligands and control (fucoidin sulfate, dextran sulfate and chondroitin sulfate) 
at 50 µg/ml for 1 h then treated with PPMO (500 nM) for 4 h in Opti-MEM® before changing 
the medium to differentiation medium and incubation for 20 h. The products of nested reverse 
transcription-PCR (RT-PCR) were examined by electrophoresis on a 2% agarose gel. The top 
band indicates full-length transcript and the bottom band represents exon-skipped transcript (B) 
C2C12 myoblasts differentiated for 1 d, then treated with either siRNA cocktail targeting 
SACRA1,2,4 and 5 (25 nM each) using Lipofectamine RNAiMax® or scrambled control siRNA 
(Cntrl. siRNA, 100 nM). After 24 h, medium was changed and cells treated with PPMO (500 
nm) as stated above. The products of nested RT-PCR were examined by gel electrophoresis and 
the percent of exon skipping was calculated using densitometry. (C) Quantitative PCR (qPCR) 
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analysis of dystrophin exon 23-skipping in tibialis anterior muscle (TA), diaphragm and heart 1 
week following intravenous injection of 10 mg/kg PPMO (Pi6a-PMO) in adult SCARA1-/- and 
wild-type (WT) C57 BL/6 mice (n=4). The percentage of exon 23-skipping of the Dmd 
transcripts was determined by normalizing exon 23-24 amplification levels to exon 20-21 levels. 
*P < 0.05; Student’s t-test; error bars represent mean ± SEM. 
 
Figure 3. Role of SRs in the uptake of tcDNA and 2’OMe. (A) Differentiated C2C12 cells 
(2.5x104/cm2) were pretreated with SR ligands including fucoidin sulfate or polyinosinic acid 
(poly I), and controls including chondroitin sulfate or polycytidylic acid (poly C), at 100 µg/ml 
for 1 h. Then cells were incubated with FITC-2’OMePS (200 nM) or FITC-tcDNA (200 nM) for 
4 h and visualized by florescence microscopy. Scale bar, 20 µm. (B) Quantitative fluorescence 
image analysis, mean fluorescence intensity was quantified using ImageJ software. *P < 0.05, 
**P < 0.01, ***P < 0.001; one-way ANOVA, error bars represent mean ± SEM. 
 
Figure 4. Interaction with SCARA1. (A) Representative images of the cellular co-localization 
of Cy5-PPMO or FITC-2’OMePS and FITC-tcDNA with rat anti-mouse SCARA1 antibody in 
differentiated C2C12 myotubes at 4 h as measured by fluorescence microscopy (Cy5- PPMO, 
FITC-tcDNA and FITC- 2’OMePS were used at 200, 500 and 500 nM, respectively). Scale bar, 
20 µm. (B) Binding experiments were performed using a Biacore 3000 system. His-tagged 
SCARA1 receptor was immobilized on the chip using an anti-his-tag antibody to give < 420 RU. 
Different ASOs in PBS were injected at 10 µL/min at 25 ºC. Data traces were zeroed in the x and 
y axis after subtraction of non-specific binding. 
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Figure 5: An illustration describing the relation between two different models of cellular 
uptake. Singular molecules follow the Lipinski rule of 5 49 (molecular weight is less than 500 
Da, lipophilicity-expressed as is less than 5, the number of hydrogen bond donators  is less than 
5 and the number of hydrogen bond acceptors is less than 10). This leads to sharp decrease in 
uptake with increasing size and charge of a molecule. That is why singular naked ASOs fail to 
cross cell-membranes. However, when they reach certain size, either by self-assembly or 
incorporation into nanoparticle-based delivery vectors, they lie within the scope of the receptor-
mediated uptake process, especially through pattern recognition receptors of the innate immune 
system such as scavenger receptors. For this process to take place the nanoparticles have to 
possess a minimum radius (rminimum, around 22 nm) 
45. Beyond an upper limit (rmaximum, around 60 
nm) uptake starts to drop once more.  Below the minimum radius, uptake is impeded by the high 
energy cost required for high curvature of the membrane for particle wrapping, and above the 
maximum radius uptake will be limited by the number of the receptors available for efficient 
particle interaction 47.  
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